Fig. 6 | Scientific Reports

Fig. 6

From: Identification of a super enhancer associated gene signature for the prognosis prediction and regulatory mechanism exploration in breast cancer

Fig. 6The alternative text for this image may have been generated using AI.

Drug sensitivity analysis. Sensitivity analysis for Alpelisib (A), Cisplatin (B), Epirubicin (C), Fulvestrant (D), Olaparib (E), Palbociclib (F), Ribociclib (G), Temozolomide (H), Vinorelbine (I), and Zoledronate (J). (K) SERS of patients who received pCR and non-PCR under Paclitaxel + Ganitumab therapy. IC50, half-maximal inhibitory concentration; ns, non-significant; high: high-risk group; low: low-risk group; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page